AG˹ٷ

STOCK TITAN

[144] Design Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144
Rhea-AI Filing Summary

Design Therapeutics filed a Form 144 reporting a proposed sale of 345,000 common shares through BTIG, LLC with an aggregate market value of $1,718,100.00. The filing lists 56,900,000 shares outstanding and shows the shares were acquired on 03/26/2021 in the open market (700,000 acquired) with cash payment.

The Form 144 indicates an approximate sale date of 08/13/2025, notes nothing to report for securities sold in the past three months, and includes the filers representation that they are not aware of any undisclosed material adverse information about the issuer.

Design Therapeutics ha presentato un Form 144 segnalando la proposta vendita di 345,000 azioni ordinarie tramite BTIG, LLC con un valore di mercato complessivo di $1,718,100.00. La dichiarazione riporta 56,900,000 azioni in circolazione e indica che le azioni sono state acquistate il 03/26/2021 sul mercato aperto (700,000 acquisite) con pagamento in contanti.

Il Form 144 indica una data di vendita approssimativa del 08/13/2025, segnala niente da dichiarare per titoli venduti negli ultimi tre mesi e include la dichiarazione del dichiarante di non essere a conoscenza di informazioni materiali sfavorevoli non divulgate sull'emittente.

Design Therapeutics presentó un Form 144 informando la propuesta de venta de 345,000 acciones ordinarias a través de BTIG, LLC por un valor de mercado agregado de $1,718,100.00. El documento indica 56,900,000 acciones en circulación y señala que las acciones fueron adquiridas el 03/26/2021 en el mercado abierto (700,000 adquiridas) con pago en efectivo.

El Form 144 señala una fecha aproximada de venta del 08/13/2025, anota nada que informar para valores vendidos en los últimos tres meses e incluye la declaración del declarante de no tener conocimiento de información adversa material no divulgada sobre el emisor.

Design Therapeutics� Form 144� 제출하여 BTIG, LLC� 통해 345,000 보통주를 � 시장 가� $1,718,100.00� 매각� 것을 보고했습니다. 제출서류에는 56,900,000 주의 유통주식수가 기재되어 있으�, 해당 주식들은 03/26/2021� 공개시장(open market)에서 현금으로 (700,000 �) 취득되었다고 적혀 있습니다.

Form 144� 대략적� 매도 예정일을 08/13/2025� 기재하고, 최근 3개월 � 매도� 증권� 대� 보고� 사항 없음으로 적시했으�, 제출자가 발행인에 관� 공개되지 않은 중대� 불리� 정보� 알고 있지 않다� 진술� 포함합니�.

Design Therapeutics a déposé un Form 144 signalant la proposition de vente de 345,000 actions ordinaires via BTIG, LLC pour une valeur de marché totale de $1,718,100.00. Le dossier indique 56,900,000 actions en circulation et précise que les actions ont été acquises le 03/26/2021 sur le marché ouvert (700,000 acquises) par paiement en espèces.

Le Form 144 mentionne une date de vente approximative au 08/13/2025, signale rien à déclarer pour les titres vendus au cours des trois derniers mois et inclut la déclaration du déclarant selon laquelle il n'est pas au courant d'informations défavorables matérielles non divulguées concernant l'émetteur.

Design Therapeutics reichte ein Form 144 ein und meldete den geplanten Verkauf von 345,000 Stammaktien über BTIG, LLC mit einem aggregierten Marktwert von $1,718,100.00. Die Meldung weist 56,900,000 ausstehende Aktien aus und gibt an, dass die Aktien am 03/26/2021 am offenen Markt (700,000 erworben) gegen Barzahlung erworben wurden.

Das Form 144 nennt ein ungefähres Verkaufsdatum am 08/13/2025, vermerkt für in den letzten drei Monaten verkaufte Wertpapiere nichts zu melden und enthält die Erklärung des Meldenden, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen über den Emittenten bekannt sind.

Positive
  • None.
Negative
  • None.

Insights

TL;DR: Routine Form 144 disclosing an intended sale of 345,000 common shares; information is factual and non-material to capital structure.

The filing documents a planned sale executed through BTIG, LLC on 08/13/2025 for an aggregate market value of $1,718,100.00. The shares were acquired on 03/26/2021 in the open market and paid for in cash. There are 56,900,000 shares outstanding reported. The notice reports no securities sold in the past three months, suggesting this is an isolated disposition rather than a pattern of recent insider selling. From a securities perspective, the disclosure is complete and procedural.

TL;DR: The Form 144 is a standard compliance disclosure; it affirms the filers certification about undisclosed material information.

The document contains the required seller representations, including that the filer does not possess undisclosed material adverse information about the issuer. The filing specifies broker details (BTIG, LLC) and includes acquisition history (open market purchase on 03/26/2021). No sales in the prior three months are reported. This is a routine governance-level disclosure that meets regulatory requirements.

Design Therapeutics ha presentato un Form 144 segnalando la proposta vendita di 345,000 azioni ordinarie tramite BTIG, LLC con un valore di mercato complessivo di $1,718,100.00. La dichiarazione riporta 56,900,000 azioni in circolazione e indica che le azioni sono state acquistate il 03/26/2021 sul mercato aperto (700,000 acquisite) con pagamento in contanti.

Il Form 144 indica una data di vendita approssimativa del 08/13/2025, segnala niente da dichiarare per titoli venduti negli ultimi tre mesi e include la dichiarazione del dichiarante di non essere a conoscenza di informazioni materiali sfavorevoli non divulgate sull'emittente.

Design Therapeutics presentó un Form 144 informando la propuesta de venta de 345,000 acciones ordinarias a través de BTIG, LLC por un valor de mercado agregado de $1,718,100.00. El documento indica 56,900,000 acciones en circulación y señala que las acciones fueron adquiridas el 03/26/2021 en el mercado abierto (700,000 adquiridas) con pago en efectivo.

El Form 144 señala una fecha aproximada de venta del 08/13/2025, anota nada que informar para valores vendidos en los últimos tres meses e incluye la declaración del declarante de no tener conocimiento de información adversa material no divulgada sobre el emisor.

Design Therapeutics� Form 144� 제출하여 BTIG, LLC� 통해 345,000 보통주를 � 시장 가� $1,718,100.00� 매각� 것을 보고했습니다. 제출서류에는 56,900,000 주의 유통주식수가 기재되어 있으�, 해당 주식들은 03/26/2021� 공개시장(open market)에서 현금으로 (700,000 �) 취득되었다고 적혀 있습니다.

Form 144� 대략적� 매도 예정일을 08/13/2025� 기재하고, 최근 3개월 � 매도� 증권� 대� 보고� 사항 없음으로 적시했으�, 제출자가 발행인에 관� 공개되지 않은 중대� 불리� 정보� 알고 있지 않다� 진술� 포함합니�.

Design Therapeutics a déposé un Form 144 signalant la proposition de vente de 345,000 actions ordinaires via BTIG, LLC pour une valeur de marché totale de $1,718,100.00. Le dossier indique 56,900,000 actions en circulation et précise que les actions ont été acquises le 03/26/2021 sur le marché ouvert (700,000 acquises) par paiement en espèces.

Le Form 144 mentionne une date de vente approximative au 08/13/2025, signale rien à déclarer pour les titres vendus au cours des trois derniers mois et inclut la déclaration du déclarant selon laquelle il n'est pas au courant d'informations défavorables matérielles non divulguées concernant l'émetteur.

Design Therapeutics reichte ein Form 144 ein und meldete den geplanten Verkauf von 345,000 Stammaktien über BTIG, LLC mit einem aggregierten Marktwert von $1,718,100.00. Die Meldung weist 56,900,000 ausstehende Aktien aus und gibt an, dass die Aktien am 03/26/2021 am offenen Markt (700,000 erworben) gegen Barzahlung erworben wurden.

Das Form 144 nennt ein ungefähres Verkaufsdatum am 08/13/2025, vermerkt für in den letzten drei Monaten verkaufte Wertpapiere nichts zu melden und enthält die Erklärung des Meldenden, dass ihm keine nicht offengelegten, wesentlichen nachteiligen Informationen über den Emittenten bekannt sind.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the Form 144 filed by Design Therapeutics (DSGN) disclose?

The Form 144 discloses a proposed sale of 345,000 common shares through BTIG, LLC with an aggregate market value of $1,718,100.00.

When is the approximate date of the proposed sale in the DSGN Form 144?

The Form 144 lists an approximate sale date of 08/13/2025.

How and when were the shares to be sold originally acquired?

The shares were acquired on 03/26/2021 in the open market; the filing shows 700,000 shares were acquired on that date and payment was in cash.

Does the Form 144 report any securities sold by the filer in the past three months?

No. The filing explicitly states "Nothing to Report" for securities sold during the past three months by the person for whose account the securities are to be sold.

What certification does the filer make in the Form 144?

The filer represents by signing the notice that they do not know any material adverse information regarding the issuer that has not been publicly disclosed.
Design Therapeutics, Inc.

NASDAQ:DSGN

DSGN Rankings

DSGN Latest News

DSGN Latest SEC Filings

DSGN Stock Data

296.13M
34.51M
35.98%
61.03%
6.14%
Biotechnology
Pharmaceutical Preparations
United States
CARLSBAD